超性心肌病的管理
Yuhui Zhang1, Marianna Adamo2, Changhong Zou1
1Heart Failure Care Unit, Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union of Medical College, National Center for Cardiovascular Diseases, Beijing, China.
Journal of cardiovascular medicine (Hagerstown, Md.)
|April 16, 2024
概括
增高性心肌病变 (HCM) 是导致心力衰竭和突然死亡的重要原因. 新兴的遗传洞察力和诸如肌肉酶抑制剂之类的新疗法为管理HCM症状和临床过程提供了希望.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 增高性心肌病变 (HCM) 是心力衰竭和心脏突然死亡的主要原因.
- 在HCM中,遗传因素和多样化的表型越来越多地被识别出来.
- 由于其患病率和严重程度,HCM对医疗保健系统产生了重大影响.
研究的目的:
- 为了呈现一个全面的概述的多变性心肌病.
- 涵盖HCM的流行病学,诊断和当前治疗策略.
- 讨论了解和管理HCM的最新进展.
主要方法:
- 对流行病学数据的文献综述.
- 对诊断标准和成像技术的分析.
- 评估当前和新兴的治疗干预措施,包括肌抑制剂.
主要成果:
- 确定HCM的关键遗传基础.
- 独特的表型表现的表征.
- 在修改HCM症状和疾病进展方面,肌酸酶抑制剂的证据.
结论:
- HCM仍然是一个关键的心血管疾病,具有显著的发病率和死亡率.
- 基因研究和向治疗的进步正在改变HCM管理.
- 在当前的时代,全面的,最新的理解对于有效的患者护理至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577
Increased pulse rate
662
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
662
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K


